The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:536-537 January 31, 2008 Number 5
NextNext

Fluorodeoxyglucose PET in Relapsing Polychondritis

 

This Article
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: We report on a case of fever of unknown origin in which 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) was instrumental in depicting cartilage inflammation, which eventually led to a histologically confirmed diagnosis of relapsing polychondritis. Relapsing polychondritis is a rare inflammatory disease that may affect cartilage throughout the body, but the diagnosis may be challenging in the absence of typical auricular or nasal involvement, as in the patient described here.1

A 67-year-old man presented with a 1.5-year history of persistent cough with clear secretions, progressive shortness of breath, sore throat, bloated stomach, low-grade fever, malaise, and weight loss. Physical examination revealed tenderness on all sternocostal junctions and in the laryngeal region. Vesicular breath sounds were decreased. The erythrocyte sedimentation rate was 130 mm per hour, and the C-reactive protein level was 20.0 mg per deciliter (normal level, <0.5). The white-cell count was 15,000 per cubic millimeter, with 86% neutrophils. The lactate dehydrogenase level was 516 U per liter (normal range, 240 to 480). All cultures and serologic tests were negative. The antinuclear factor level was normal, and the level of c-antineutrophilic cytoplasmic antibodies was slightly increased.

The patient's condition improved with the administration of corticosteroids for the treatment of asthma, but he did not have a complete recovery. As part of a diagnostic workup, the patient underwent whole-body PET with FDG (FDG-PET). The imaging study revealed marked tracer uptake in all rib cartilages, as well as in the larynx, trachea, and major bronchi (Figure 1A). Surgical biopsy of the 12th rib cartilage, shown to be involved on PET, provided histologic confirmation of the diagnosis.

Figure 1
View larger version (53K):
[in this window]
[in a new window]
Get Slide
 
Figure 1. Positron-Emission Tomographic (PET) Studies with 18F-fluorodeoxyglucose in a Patient with Relapsing Polychondritis.

Transverse slices at the level of the larynx (top) and coronal slices at the rib cartilages (middle) and through the tracheobronchial tree (bottom) show increased tracer uptake before the diagnosis of relapsing polychondritis (Panel A). The cartilaginous tracer accumulation is not visible during remission (Panel B).

 
Treatment with methylprednisolone and dapsone induced disease remission. After 5 months, while receiving a daily dose of 8 mg of methylprednisolone, the patient had a relapse. The dose of methylprednisolone was increased to 32 mg, and cyclophosphamide (at a daily dose of 100 mg) was administered. At that time, severe retro-obstructive bilateral pneumonia developed. Antibiotics were temporarily added to the regimen, and endobronchial stents were inserted. Nine months after his condition had been diagnosed, the patient again had a clinical and biochemical remission, and cartilaginous tracer accumulation had largely disappeared on a new PET study (Figure 1B).

Evidence supporting the pivotal role of FDG-PET in the diagnosis of fever of unknown origin is increasing steadily.2,3 The case we describe illustrates the role of FDG-PET in the diagnosis of relapsing polychondritis, especially in patients who do not have typical manifestations. By localizing sites of active inflammation, FDG-PET may guide the selection of a biopsy site.2 Like other reported cases, this case shows the correlation between the findings on FDG-PET and disease activity, as assessed by clinical and laboratory measures.4


Frank De Geeter, M.D., Ph.D.
Stefaan J. Vandecasteele, M.D., Ph.D.
Saint John's General Hospital
8000 Brugge, Belgium
frank.degeeter{at}azbrugge.be

References

  1. Gergely P Jr, Poór G. Relapsing polychondritis. Best Pract Res Clin Rheumatol 2004;18:723-738. [CrossRef][Medline]
  2. Blockmans D, Knockaert D, Maes A, et al. Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001;32:191-196. [CrossRef][Web of Science][Medline]
  3. Bleeker-Rovers CP, Vos FJ, Mudde AH, et al. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 2007;34:694-703. [CrossRef][Web of Science][Medline]
  4. Walter MA, Melzer RA, Schindler C, Müller-Brand J, Tyndall A, Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005;32:674-681. [CrossRef][Web of Science][Medline]

 

This Article
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.